Skip to main content
OTCMKTS:GENSF

Genus Stock Forecast, Price & News

$66.00
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$66.00
▼
$66.00
50-Day Range
$66.00
▼
$70.40
52-Week Range
$54.00
▼
$77.00
VolumeN/A
Average Volume263 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GENSF News and Ratings via Email

Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter.


Genus logo

About Genus

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Headlines

Genus (OTCMKTS:GENSF) Trading Up 1.4%
Genus (OTCMKTS:GENSF) Trading Up 1.4%
May 7, 2021 |  americanbankingnews.com
If You Had Bought Genus (LON:GNS) Stock Five Years Ago, You Could Pocket A 227% Gain Today
If You Had Bought Genus (LON:GNS) Stock Five Years Ago, You Could Pocket A 227% Gain Today
April 8, 2021 |  finance.yahoo.com
Wizz co-founder capitalises on share resurgence
Wizz co-founder capitalises on share resurgence
March 5, 2021 |  finance.yahoo.com
Genus reports strong interim results
Genus reports strong interim results
February 25, 2021 |  lse.co.uk
Genus Posts "Very Strong" Interim Results Despite Covid-19 Impact
Genus Posts "Very Strong" Interim Results Despite Covid-19 Impact
February 25, 2021 |  lse.co.uk
UK firm Genus sees challenges as it restocks China pig farms
UK firm Genus sees challenges as it restocks China pig farms
February 25, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GENSF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genusplc.com
Phone44 1256 347100
Employees3,100
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.66 out of 5 stars

Medical Sector

1334th out of 2,044 stocks

Biotechnology Industry

66th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Genus (OTCMKTS:GENSF) Frequently Asked Questions

Is Genus a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Genus stock.
View analyst ratings for Genus or view top-rated stocks.

What stocks does MarketBeat like better than Genus?

Wall Street analysts have given Genus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Genus' key executives?

Genus' management team includes the following people:
  • Mr. Stephen Wilson, CEO & Exec. Director (Age 61, Pay $2.16M)
  • Ms. Alison Henriksen, CFO & Exec. Director (Age 54, Pay $993.38k)
  • Dr. William Christianson, Chief Operating Officer
  • Dr. Elena Rice, Head of R&D and Chief Scientific Officer
  • Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
  • Ms. Angelle R. Rosata, Group HR Director
  • Mr. Jerry Thompson, Chief Operating Officer of Genus ABS Beef
  • Dr. Nate Zwald, Chief Operating Officer of Genus ABS Dairy
  • Ms. Janet Duane, Group Financial Controller

Who are some of Genus' key competitors?

Some companies that are related to Genus include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of GENSF's competitors.

What is Genus' stock symbol?

Genus trades on the OTCMKTS under the ticker symbol "GENSF."

How do I buy shares of Genus?

Shares of GENSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genus' stock price today?

One share of GENSF stock can currently be purchased for approximately $66.00.

How many employees does Genus have?

Genus employs 3,100 workers across the globe.

What is Genus' official website?

The official website for Genus is www.genusplc.com.

How can I contact Genus?

The company can be reached via phone at 44 1256 347100.


This page was last updated on 5/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.